First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
Healthcare
$44.50 -4.87%
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
52W Low $14.72High $26.80
Volume 0.75M
Average 0.43M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$142.93M
FY 2025 · Annual
Investing Cash Flow
$228.03M
FY 2025 · Annual
+139.0% YoYFinancing Cash Flow
$30.01M
FY 2025 · Annual
-74.5% YoYCash Flow Statement
USD
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (106.15M) | (163.71M) | (166.09M) |
| Depreciation & Amortization | 2.38M | 2.4M | 2.42M |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 18.39M | 26.83M | 32.3M |
| Change in Working Capital | 2.9M | 18.99M | (1.52M) |
| Accounts Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Accounts Payables | 8.39M | 17.81M | 0 |
| Other Working Capital | (5.49M) | 1.18M | (1.52M) |
| Other Non-Cash Items | (10.52M) | (10.31M) | (10.04M) |
| Operating Cash Flow | (93M) | (125.81M) | (142.93M) |
| Capital Expenditures | (807K) | (358K) | (87K) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | (303.92M) | (380.38M) | 0 |
| Sales of Investments | 449.48M | 476.13M | 0 |
| Other Investing Activities | 0 | 0 | 228.12M |
| Investing Cash Flow | 144.75M | 95.4M | 228.03M |
| Debt Repayment | 0 | 0 | 0 |
| Common Stock Issued | 0 | 117.52M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 30.01M |
| Financing Cash Flow | (87.09M) | 117.52M | 30.01M |
| Effect of Forex Changes | 0 | 0 | 0 |
| Net Change in Cash | (35.34M) | 87.12M | 115.12M |
| Free Cash Flow | (93.81M) | (126.16M) | (143.01M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$166.1M
+ D&A$2.4M
+ Stock-Based Comp$32.3M
+ Deferred Tax$0
- Working Capital-$1.5M
- Other Non-Cash-$10.0M
= Operating Cash Flow-$142.9M
- Capex-$87.0K
= Free Cash Flow-$143.0M
Analysis
FY2025 free cash flow is -$143.0M. FCF conversion is 86.1% of net income. Operating cash flow was -$142.9M, with capex of -$87.0K. The largest bridge item is Stock-Based Comp at $32.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 12, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| 424B3 | 424B3 filing | Nov 4, 2026 | |
| 424B3 | 424B3 filing | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 |
Does TRAX generate free cash flow?
First Tracks Biotherapeutics Inc (TRAX) generated -$143.01M of free cash flow in fiscal 2025.
How much operating cash flow does TRAX produce?
Operating cash flow was -$142.93M, before capital expenditures of $87,000.00.
Continue the stock analysis
Jump to another research area for this company.